Public Company News
Yunji to Report Fourth Quarter and Full Year 2021 Financial Results on March 17, 2022
HANGZHOU, China, March 7, 2022 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ: YJ), a leading membership-based social e-commerce platform, today announced that it plans to release its fourth quarter and full year 2021 financial results before the market opens onThursday, March 17, ...
2022-03-07 19:00
3171
CooTek to Announce Fourth Quarter and Fiscal Year 2021 Unaudited Financial Results on March 15, 2022
SHANGHAI, March 7, 2022 /PRNewswire/ -- CooTek (Cayman) Inc. (NYSE: CTK) ("CooTek" or the "Company"), a fast-growing global mobile internet company, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year 2021 endedDecember 31, 2021, before the o...
2022-03-07 17:30
2581
Tuniu to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 17, 2022
NANJING, China, March 7, 2022 /PRNewswire/ -- Tuniu Corporation (NASDAQ:TOUR) ("Tuniu" or the "Company"), a leading online leisure travel company inChina, today announced that it plans to release its unaudited financial results for the fourth quarter and fiscal year endedDecember 31, 2021, before...
2022-03-07 16:00
2493
TCI Enters into Strategic Alliance with VeCollal(R) and CDMO the World's First, Science-based vegan collagen alternative
TAIPEI, March 7, 2022 /PRNewswire/ -- Today TCI (8436TT) announced its strategic alliance with VeCollal® , the well-knownBelgium based vegan collagen alternative company which has joined hands with TCI. The VeCollal® vegan collagen alternative has been designed to have the identical amino acid pr...
2022-03-07 16:00
3263
Keymed has been included as eligible stocks of the Shenzhen-Hong Kong Stock Connect
CHENGDU, China, March 7, 2022 /PRNewswire/ -- Keymed Biosciences Inc. (2162.HK) is pleased to announce that the shares of the Company have been included as eligible stocks of the Shenzhen-Hong Kong Stock Connect with effect fromMarch 7, 2022, pursuant to the announcement issued by the Shenzhen St...
2022-03-07 15:57
3031
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of KX-826 in China for the Treatment of Androgenetic Alopecia in Female Patients
SUZHOU, China, March 6, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment of 160 patients for its...
2022-03-07 08:18
4100
Tuya to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022 Eastern Time
SANTA CLARA, Calif., March 4, 2022 /PRNewswire/ -- Tuya Inc. ("Tuya" or the "Company") (NYSE: TUYA), a global leading IoT cloud development platform, today announced that it will report its fourth quarter and full year 2021 unaudited financial results onMonday, March 14, 2022, after the U.S. mark...
2022-03-05 05:30
6214
iQIYI Announces Private Placement Financing of US$285 Million
BEIJING, March 4, 2022 /PRNewswire/ -- iQIYI, Inc. (Nasdaq: IQ) ("iQIYI" or the "Company"), an innovative market-leading online entertainment service inChina, today announced that the Company has entered into subscription agreements with Baidu and a consortium of financial investors that include ...
2022-03-04 20:00
6522
CLPS Incorporation Reports Financial Results for the First Half of Fiscal Year 2022
HONG KONG, March 4, 2022 /PRNewswire/ -- CLPS Incorporation (the "Company" or "CLPS") (Nasdaq: CLPS), today announced its unaudited financial results for the six months endedDecember 31, 2021, or the first half of the Company's fiscal year 2022. First Half of Fiscal 2022 Highlights (all results ...
2022-03-04 19:30
6340
Yalla Group Limited to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022 Eastern Time
DUBAI, UAE, March 4, 2022 /PRNewswire/ -- Yalla Group Limited ("Yalla" or the "Company") (NYSE: YALA), the leading voice-centric social networking and entertainment platform in theMiddle East and North Africa (MENA), today announced that it will report its unaudited financial results for the four...
2022-03-04 19:00
4263
Trip.com Group Ltd. to Report Fourth Quarter and Full Year of 2021 Financial Results on March 23, 2022 U.S. Time
SHANGHAI, March 4, 2022 /PRNewswire/ -- Trip.com Group Ltd. (Nasdaq: TCOM and HKEX: 9961), a leading one-stop travel service provider of accommodation reservation, transportation ticketing, packaged tours and corporate travel management, will announce its fourth quarter and full year of 2021 resu...
2022-03-04 18:00
3305
Qudian Inc. Provides Business Updates on WLM KIDS
XIAMEN, China, March 4, 2022 /PRNewswire/ -- Qudian Inc. ("Qudian" or the "Company") (NYSE: QD), a leading technology platform empowering the enhancement of online consumer finance experience inChina, today announced that it plans to significantly downsize its WLM KIDS business. The Company laun...
2022-03-04 18:00
4475
111, Inc. Reaches Strategic Partnership on Direct Supply with Beilin Pharmaceutical to Blaze New Trails in Digital Development of Chinese Patent Medicine
SHANGHAI, March 4, 2022 /PRNewswire/ -- On February 23, 2022, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company inChina, signed a strategic cooperation agreement on direct supply with Xi'an Beilin Pharmaceutical Co., Ltd. ("Beilin Pharmaceutical")...
2022-03-04 17:24
2659
FinVolution Group to Report Fourth Quarter and Fiscal Year 2021 Financial Results on Monday, March 14,2022
SHANGHAI, March 4, 2022 /PRNewswire/ -- FinVolution Group ("FinVolution", or the "Company") (NYSE: FINV), a leading fintechplatform, today announced that it will report its fourth quarter and fiscal year 2021 unaudited financial results, onMonday, March 14, 2022, after the close of U.S. markets. ...
2022-03-04 16:00
4893
Genome and Company announces Clinical Trial Collaboration with MSD to evaluate 'GEN-001' in combination of KEYTRUDA® (pembrolizumab) in phase 2 clinical trial in biliary tract cancer patients
SEOUL, South Korea, March 3, 2022 /PRNewswire/ -- Genome and Company (KOSDAQ: 314130, CEO∙CTO: Jisoo Pae∙Hansoo Park), a leading global microbiome anti-cancer drug development company, announced it has entered into a first Clinical Trial Collaboration and Supply Agreement (CTCSA) with MSD (a trad...
2022-03-04 09:30
3039
Splitit announces FY21 full-year results with Record MSV surpassing $500M annualised run rate
- Record annual Merchant Sales Volume (MSV) of US$396M, an increase of 61% Year on Year (YoY), with an annualised run rate overUS$500M based on Q4 - Active Merchants accelerated to 1.25K, up 60% YoY, and Active Shoppers increased to330K, up 43% YoY - Google selects Splitit as its first ins...
2022-03-04 04:26
5107
Baidu Launches AI Platform to Enable on-Device, Real-Time Translation from Speech to Hand Gestures
BEIJING, March 3, 2022 /PRNewswire/ -- Baidu AI Cloud, a leading AI cloud provider, launched an AI sign language platform able to generate digital avatars for sign language translation and live interpretation within minutes. Released as a new offering of Baidu AI Cloud's digital avatar platform X...
2022-03-03 22:37
3978
Hanwha Solutions supplies Samsung Electronics with recycled ocean-bound materials for Galaxy devices
* The Company's wholly-owned subsidiary Hanwha Compound produces eco-conscious materials using discarded fishing nets. * Use of recycled ocean-bound materials across Samsung's mobile devices will help improvemarine biodiversity and fulfill ESG mandate. * "Expanding them into automotive elect...
2022-03-03 22:00
3010
Claudin18.2 CAR T Cells (CT041) Receives Approval to Initiate A Confirmatory Phase II Clinical Trial for advanced GC/GEJ in China
SHANGHAI, March 3, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, today announced that the Center for Drug Evaluation (CDE) of the National Medic...
2022-03-03 21:50
2791
I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer
SHANGHAI and GAITHERSBURG, Md., March 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the U.S. Food and Drug Administration (FDA) has gr...
2022-03-03 21:00
2357
Week's Top Stories
Most Reposted
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
[Picked up by 309 media titles]
2026-07-30 10:45
Hyatt Regency Kuala Lumpur At KL Midtown: A Refined Urban Retreat Recognised For Design Excellence
[Picked up by 295 media titles]
2026-08-04 07:00
J.P. Morgan Private Bank Earns Record 10 Accolades at The Asset Triple A Private Capital Awards 2026
[Picked up by 294 media titles]
2026-07-30 15:00Vitafoods Asia Announces Strategic Move to Kuala Lumpur for 2027 Edition
[Picked up by 291 media titles]
2026-08-04 14:30
Most Read
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
2026-07-30 10:45
18346
